Could local surgery improve survival in de novo stage IV breast cancer?

BMC Cancer

Table 1 Characteristics of patients who were diagnosed with de novo stage IV breast cancer

Variable	No. Patients(N = 313)	Percentage
Age at diagnosis
≤ 50	189	39.6
> 50	124	60.4
Menopause status
Menses	193	61.7
Menopause	115	36.7
Unknown	5	1.6
Biopsy
Mass resection	27	8.6
Core needle	229	73.2
Fine needle	1	0.3
Unknown	56	17.9
Tumor size
≤ 5 cm	174	55.6
> 5 cm	120	38.3
Unknown	19	6.1
Lymph node involvement
N₀	28	8.9
N₁	44	14.1
N₂	71	22.7
N₃	129	41.2
Unknown	41	13.1
Hormone receptor status
+	212	67.7
-	94	30.0
Unknown	7	2.2
HER2 receptor status
Amplified	132	42.2
No-amplified	161	51.4
Not known or equivocal(2+)	20	6.4
Molecular subtype
Luminal A	55	17.6
Luminal B	141	45.0
HER2	56	17.9
Triple negative	33	10.5
Unknown*	28	8.9
Surgery
Yes	188	60.1
No	125	39.9
Type of surgery
Modified radical mastectomy	181	96.3
Lumpectomy	3	1
Simple mastectomy	4	1.3
Margin status
Negative	184	97.9
Positive	4	2.1
Endocrine therapy$
Yes	123	39.3
No	190	60.7
Anti-HER2 therapy$
Yes	71	22.7
No	239	76.4
Unknown	3	1
Chemotherapy(first line regimen)$
CAF/CEF	9	2.9
Taxane based/taxane +anthracyline	241	77.0
Platinum based	17	5.4
Others	20	6.4
Unknown	26	8.3
Bisphosphonate
Yes	92	29.4
No	221	70.6
OFS*
Yes	58	18.5
No	255	81.5
Radiotherapy
Yes	99	31.6
No	184	58.8
Unknown	30	9.6
Viscera metastasis
Yes	167	53.4
No	146	46.6
Bone metastasis
Yes	171	54.6
No	142	45.4
CNS metastasis*
Yes	11	3.5
No	302	96.5
Soft tissue metastasis
Yes	139	44.4
No	174	55.6
No. of metastasis sites
≤ 3	288	92.0
> 3	25	8.0
Overall survival(months)
Median	62	–
95% Confidence interval	45.79–78.21	–

Abbreviation: *OFS = ovarian function suppression; CNS = central nervous system; ^$Endocrine therapy were subsequent to chemotherapy, anti-HER2 therapy were incorporated into or subsequent to chemotherapy

ISSN: 1471-2407